Condition (MeSH)
Adenocarcinoma in Situ
ClinicalTrials.gov lists 11 trials for Adenocarcinoma in Situ or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Adenocarcinoma in Situ itself; the rest are tagged with a narrower condition beneath it.
When did Adenocarcinoma in Situ trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2016 | 2 |
| 2013 | 1 |
| 2011 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adenocarcinoma in Situ trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 6 |
How many Adenocarcinoma in Situ trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 2 |
| Terminated | 3 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adenocarcinoma in Situ trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 2 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 9vHPV Vaccine | 1 |
| V501 | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Adenocarcinoma in Situ trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abortion induced | 4 | 1 |
| Abortion spontaneous | 1 | 1 |
| Foetal malpresentation | 1 | 1 |
| Peritonsillitis | 1 | 1 |
| Subarachnoid haemorrhage | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Adenocarcinoma in Situ? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. | The Lancet. Respiratory medicine | 2024 | Yes |
| Cervical intraepithelial neoplasia and the risk of spontaneous preterm birth: A Dutch population-based cohort study with 45,259 pregnancy outcomes. | PLoS medicine | 2021 | Yes |
| Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations. | Obstetrics and gynecology | 2020 | Yes |
| A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2018 | Yes |
| Early metal stent insertion fails to prevent stricturing after single-stage complete Barrett's excision for high-grade dysplasia and early cancer. | Gastrointestinal endoscopy | 2015 | Yes |
Showing 5 of 10 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.